The Vienna-based startup was purchased 100% by the Swiss health industry giant. The app’s tech will help inform Roche’s digital strategy for the diabetes market moving forward. “[The deal] means that we, people with diabetes, will be in the driver’s seat, supported by the global leader in diabetes therapy,” said mySugr in a statement. mySugr will continue to operate on its own.
The app is used by diabetics to track their condition in between doctor visits. It has one million users globally.
Prior to the acquisition, Roche’s venture fund had invested in the startup, which has raised over $6 million in total VC funding.